| 发明名称 | Kappa-opiate agonists for the treatment of diarrhea-predominant irritable bowel syndrome | ||
| 摘要 | The present invention concerns methods useful in treating a subject having diarrhea-predominant IBS (IBS-D) by administering N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide and/or a pharmaceutically acceptable salt thereof to the subject. | ||
| 申请公布号 | US8877800(B2) | 申请公布日期 | 2014.11.04 |
| 申请号 | US201012940979 | 申请日期 | 2010.11.05 |
| 申请人 | Tioga Pharmaceuticals, Inc. | 发明人 | Mangel Allen |
| 分类号 | A61K31/40 | 主分类号 | A61K31/40 |
| 代理机构 | Morrison & Foerster LLP | 代理人 | Morrison & Foerster LLP |
| 主权项 | 1. A method for treating human subjects having diarrhea-predominant irritable bowel syndrome (IBS-D), comprising administering a pharmaceutical composition comprising 0.3 mg to 5 mg per day of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide or a pharmacologically acceptable salt thereof to said subjects, wherein said administration normalizes bowel motility. | ||
| 地址 | San Diego CA US | ||